CANDESARTAN CILEXETIL | A078702 | MYLAN PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Attachment 1 - ATACAND - Prescription Drug Product List RE Suitability Petiti... FDA-2021-P-0510 · 6 docket documents Hyman, Phelps & McNamara, P.C. filed a suitability petition regarding Atacand (candesartan cilexetil), a prescription drug product, requesting that the FDA determine the suitability of the drug for inclusion on the Prescription Drug Product List. | Suitability | 2021-05-26 | Granted | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.5729
per ea
Lowest NADAC/Unit
$0.4777
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378322577CANDESARTAN CILEXETIL 8 MG TAB | $0.5729 | EA | Generic | — | 2026-06-17 |
| 00378322593CANDESARTAN CILEXETIL 8 MG TAB | $0.5729 | EA | Generic | — | 2026-06-17 |
| 00378323293CANDESARTAN CILEXETIL 32 MG TB | $0.5392 | EA | Generic | — | 2026-06-17 |
| 00378323277CANDESARTAN CILEXETIL 32 MG TB | $0.5392 | EA | Generic | — | 2026-06-17 |
| 00378322477CANDESARTAN CILEXETIL 4 MG TAB | $0.5221 | EA | Generic | — | 2026-06-17 |
| 00378322493CANDESARTAN CILEXETIL 4 MG TAB | $0.5221 | EA | Generic | — | 2026-06-17 |
| 00378323193CANDESARTAN CILEXETIL 16 MG TB | $0.4777 | EA | Generic | — | 2026-06-17 |
| 00378323177CANDESARTAN CILEXETIL 16 MG TB | $0.4777 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.